Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
This announcement reaffirms the Scottish Medicines Consortium’s decision of 10 February 2025, meaning that no disease-modifying therapies for Alzheimer’s disease are currently approved for use in Scotland.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
From in-person high level engagements in Lima to Buenos Aires, to a digital campaign partnership providing regionally specific resources, May has proven to be an action-packed month in the Americas region. ADI Regional Director for the America’s provides his highlights from across the region including advocacy work in Argentina and Peru, alongside a public awareness campaign in partnership with the Carlos Slim Foundation.
ADI is highlighting the testimonies of those undertaking health tourism to access Alzheimer's disease treatments across the world. Recent significant advancements have led to the development of disease-modifying therapies designed to slow progression. However, access remains highly fragmented, leading to the the onset of people travelling for treatment, or health tourism, for those that have the means.